Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CF PharmTechHKSE:02652 +0.81%15 ROE % is 0.21% as of Dec. 2025, which is 83% below its 10-year median of 1.23. GuruFocus rates HKSE:02652 with a GF Score™ of 15/100. The stock has 5 warning signs investors should review. Among 935 Drug Manufacturers companies, CF PharmTech ranks worse than 67.81% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. CF PharmTech's annualized net income for the quarter that ended in Dec. 2025 was HK$2.7 Mil. CF PharmTech's average Total Stockholders Equity over the quarter that ended in Dec. 2025 was HK$1,312.5 Mil. Therefore, CF PharmTech's annualized ROE % for the quarter that ended in Dec. 2025 was 0.21%.
The historical rank and industry rank for CF PharmTech's ROE % or its related term are showing as below:
HKSE:02652'
s ROE % Range Over the Past 10 Years
Min: -5.73 Med: 1.23 Max: 3.54
Current: 0.21
During the past 4 years, CF PharmTech's highest ROE % was 3.54%. The lowest was -5.73%. And the median was 1.23%.
HKSE:02652's ROE % is ranked worse than 67.81% of 935
companies
in the Drug Manufacturers industry
Industry Median: 5.87
vs HKSE:02652: 0.21
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is one times the annual (Dec. 2025) net income data. The Revenue data used here is one times the annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
CF PharmTech ROE % Related Terms
CF PharmTech ROE % Historical Data
* Premium members only.
The historical data trend for CF PharmTech's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CF PharmTech ROE % Chart
CF PharmTech Annual Data
Trend
Dec22
Dec23
Dec24
Dec25
ROE %
-5.73
3.54
2.25
0.21
CF PharmTech Semi-Annual Data
Dec22
Dec23
Dec24
Dec25
ROE %
-5.73
3.54
2.25
0.21
HKSE:02652 vs ZTS: ROE % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, CF PharmTech's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CF PharmTech ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CF PharmTech's ROE % distribution charts can be found below:
* The bar in red indicates where CF PharmTech's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is one times the annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
CF PharmTech (HKSE:02652) has a ROE % of 0.21% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on CF PharmTech and its competitors. This is 83% below median its historical median of 1.23. According to the industry distribution chart, CF PharmTech ranks #634 out of 935 companies in the Drug Manufacturers industry, placing it in the top 67.8%.
Is CF PharmTech's ROE % too high?
CF PharmTech's current ROE % of 0.21% is 83% below median its 10-year median of 1.23. The Drug Manufacturers industry median ROE % is 5.87. CF PharmTech's value of 0.21% is 96.4% below this industry median. Based on the distribution chart, CF PharmTech ranks #634 out of 935 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, CF PharmTech has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does CF PharmTech's ROE % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, CF PharmTech ranks #634 out of 935 companies for ROE %. This places CF PharmTech in the lower half of its industry. The industry median ROE % is 5.87. CF PharmTech's value of 0.21% is 96.4% below this benchmark. While the company's 10-year median is 1.23 vs. the industry median of 5.87, CF PharmTech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 5.87, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CF PharmTech's current ROE % of 0.21% is 96.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on CF PharmTech and its competitors. For the Drug Manufacturers industry, the median ROE % is 5.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CF PharmTech's current ROE % is 0.21%, which is 83% below median its own 10-year median of 1.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CF PharmTech stock overvalued right now?
CF PharmTech (HKSE:02652) has a current ROE % of 0.21%. The current ROE % is 0.21%, which is 83% below median its 10-year median of 1.23 and 96.4% below the Drug Manufacturers industry median of 5.87. CF PharmTech's overall GF Score™ is 15/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For CF PharmTech (HKSE:02652), the current ROE % is 0.21% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CF PharmTech Inc is engaged in inhalation drug delivery technology. It is dedicated to building multidisciplinary bridges between complex formulations and unmet clinical needs. The Company is a specialist in the development of complex inhalation formulations with high barriers to entry, and a platform-based pharmaceutical company with integrated capabilities spanning device engineering, precision drug delivery, international regulatory filing, and commercialization. Leveraging its self-developed, globally integrated end-to-end capabilities, from exhalation-powered nasal spray delivery systems and liposomal inhalation technology to small interfering RNA (siRNA) nucleic acid delivery platforms. Its therapeutic areas encompass respiratory diseases and nasal diseases.
15GF Score
Get the complete analysis for HKSE:02652
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02652 has been successfully added to your 
